An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors
- 1 April 1998
- journal article
- review article
- Published by Elsevier in American Heart Journal
- Vol. 135 (4) , s43-s55
- https://doi.org/10.1016/s0002-8703(98)70297-2
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC studyAmerican Heart Journal, 1998
- Abciximab therapy in percutaneous intervention: Economic issues in the United StatesAmerican Heart Journal, 1998
- Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade With Percutaneous Coronary InterventionJAMA, 1997
- Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary RevascularizationJournal of the American College of Cardiology, 1997
- Increased Risk of Non-Q Wave Myocardial Infarction After Directional Atherectomy Is Platelet Dependent: Evidence From the EPIC TrialJournal of the American College of Cardiology, 1996
- Economic Assessment of Platelet Glycoprotein IIb/IIIa Inhibition for Prevention of Ischemic Complications of High-Risk Coronary AngioplastyCirculation, 1996
- Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarctionThe American Journal of Cardiology, 1996
- 935-34 Special Considerations for Diabetics Receiving Platelet IIb/IIIa Antagonists During Coronary Interventions: Results from the EPIC TrialartJournal of the American College of Cardiology, 1995
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsThe Lancet, 1994
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994